Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Characterization of Doxycycline Pharmacokinetics and Adherence

The purpose of this study is to evaluate the effect of body changes on doxycycline concentrations for different dosing schedules. This study will involve a single dose phase and a multiple dose phase. Healthy individuals who do not have a sexually transmitted infection (STI), including acute (e.g., gonorrhea or chlamydia) or chronic (e.g., HIV or HSV-2) infections will be enrolled in this study. Study participants will be randomized to a dosing schedule in each phase and come to the research clinic throughout their time on study for sample collection. Study participants that choose to enroll in this study will be enrolled for about 37 days.

Participants needed: 16
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: HIV Prevention Trials NetworkUpdated: Aug 10, 2026Locations: 1
Eligibility criteria

Aged 18 to 65 years of age at the time of screening [+12]

Per participant report, planned or active use of any anticonvulsants at screenin... [+11]

Status: Not yet recruiting

Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy

Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young Men

Participants needed: 400
Trial details
Phase: Phase 3Age: 18-29Biological sex: MaleType: InterventionalSponsor: HIV Prevention Trials NetworkUpdated: Jun 22, 2026Locations: 5
Eligibility criteria

Men ages 18 - 29 years [+13]

Participated in HPTN 113-01 [+8]

Status: Not yet recruiting

Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR

To evaluate adherence to a single dual-prevention pill (DPP) compared with a two-pill regimen (2PR) for pre-exposure prophylaxis (PrEP) and pregnancy prevention in women without HIV.

Participants needed: 300
Trial details
Phase: Phase 2Age: 16-39Biological sex: FemaleType: InterventionalSponsor: HIV Prevention Trials NetworkUpdated: Feb 19, 2026Locations: 3
Eligibility criteria

Age 16 through 39 years old (inclusive) at Screening. [+13]

Intolerance, adverse reaction, or laboratory abnormality associated with PrEP us... [+6]